Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The common polymorphism rs4994 [c. T387C, p. Trp64Arg (W64R)] of the lipolysis regulator beta-3-adrenergic receptor (ADRB3) was identified as a marker in the pathogenesis of hyperuricemia. As gout is characterized by elevated serum concentrations of uric acid, we investigated ADRB3 as a potential candidate for gout.
Methods: This was a prospective case-control study in a group of 421 male patients with gout and 312 gout-free male controls to genotype the single-nucleotide polymorphism rs4994 of ADRB3 gene.
Results: Our results showed that the C allele carrier confers a significantly higher risk for development of gout [chi-square = 4.91, df = 1, p = 0.027, OR 1.95 (adjusted by age, total cholesterol level, and body mass index), 95% CI 1.22-3.13 by dominant mode]. There was significantly higher uric acid level in carriers of the Arg64/Arg64 genotype in controls compared to non-carriers (480.5 mmol/l vs 315.0 mmol/l, respectively).
Conclusion: ADRB3 rs4994 polymorphism is a potential candidate for the pathogenesis of gout in a male Chinese population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.101037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CL316,243 and Skeletal Muscle Metabolism: Role of Sex and Estrogen Receptor Beta.
J Endocrinol
September 2025
University of Missouri, Columbia, MO.
Purpose: CL316,243 (CL), a beta 3 adrenergic receptor (B3-AR) agonist has 'exercise mimetic' effects in adipose tissue (AT). CL may also positively affect skeletal muscle (SM), yet the role of estrogen receptor beta (ERβ) in mediating SM-specific effects of CL is not known. We investigated the effects of CL on SM metabolism, as well as the role played by ERβ.
View Article and Find Full Text PDFAdvancements in Beta-Adrenergic Therapy and Novel Personalised Approach for Portal Hypertension: A Narrative Review.
Life (Basel)
July 2025
Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Liver cirrhosis is a chronic progressive disease marked by the transition from a compensated to a decompensated stage, associated with severe complications. Central to this progression is portal hypertension, which results from increased intrahepatic vascular resistance and endothelial dysfunction, as well as splanchnic vasodilation and an augmented circulatory state. Non-selective beta-blockers (NSBBs) remain the standard of care for portal hypertension, reducing portal pressure by lowering cardiac output via beta-1 receptor blockade and decreasing splanchnic blood flow through beta-2 receptor antagonism.
View Article and Find Full Text PDFRepurposing Drug Metabolites into Dual β-Adrenergic Receptor-Carbonic Anhydrase Modulators as Potential Tools for Ocular Disorders.
J Med Chem
August 2025
NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, Florence 50019, Italy.
We report the regioselective chemical derivatization of ()-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol, the primary metabolite of the β-Adrenergic Receptor (β-AR) agonist mirabegron, with prototypical Carbonic Anhydrase Inhibitors (CAIs) to afford the carbamates and the ureido derivatives . Such compounds were endowed with distinct inhibition profiles for the human (h) Carbonic Anhydrases (CAs) and showed preferential agonisms for the β-AR subtype. Among them, induced remarkable intraocular pressure (IOP) lowering in an transient model of ocular hypertension, with the maximal effect at 120 min post-administration at 1% w/v concentration.
View Article and Find Full Text PDFExploring the role of β2- and β3-adrenergic receptors in cystic fibrosis.
Pulm Pharmacol Ther
September 2025
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II Naples, Italy; CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145, Naples, Italy.
Cystic fibrosis (CF) is an autosomal recessive disorder that affects multiple organs, with clinical manifestations, disease progression, and response to therapy varying among individuals. This effect is mainly caused by mutations in the gene encoding for the CF transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel. In recent decades, other genes and their allelic variants, beyond CFTR mutations, have been proposed as genetic modifiers of CF phenotype.
View Article and Find Full Text PDFControl of physiologic glucose homeostasis via hypothalamic modulation of gluconeogenic substrate availability.
Mol Metab
September 2025
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:
Objectives: The brain mobilizes glucose in emergency situations such as hypoglycemia as well as during day-to-day physiology such as fasting. While most hypothalamic neuronal populations that contribute to glucose mobilization also contribute to other aspects of metabolism, neurons in the ventromedial nucleus of the hypothalamus that express the cholecystokinin b receptor (VMH neurons) support glucose production during hypoglycemia without controlling energy homeostasis. However, their role in day-to-day glucose physiology and the mechanisms they engage to support glucose mobilization is unclear.
View Article and Find Full Text PDF